



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 207/26, 211/74, 223/08, 405/04	A1	(11) International Publication Number: WO 98/13344 (43) International Publication Date: 2 April 1998 (02.04.98)
(21) International Application Number: PCT/US97/16432 (22) International Filing Date: 16 September 1997 (16.09.97) (30) Priority Data: 60/026,748 26 September 1996 (26.09.96) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; P.O. Box 4000, Princeton, NJ 08543-4000 (US). (72) Inventor: KIM, Kyoung, Soon; 11 Le Park Drive, Lawrenceville, NJ 08648 (US). (74) Agents: HOFFMAN, Frank, P. et al.; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: A PROCESS FOR THE PREPARATION OF CHIRAL KETONE INTERMEDIATES USEFUL FOR THE PREPARATION OF FLAVOPIRIDOL AND ANALOGS <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>(I)</p> </div> <div style="text-align: center;">  <p>(III)</p> </div> </div> (57) Abstract <p>A process for the preparation of compounds of formula (I) wherein R¹, R², R³, m, n and q are as defined herein; which comprises the steps of (a) reacting a compound of formula (III) with a chiral acid in an organic solvent to form a salt of a compound of formula (I) and (b) treating the salt of a compound of formula (I) with an aqueous base to obtain the compounds of formula (I). Compounds of formula (I) are intermediates useful in the preparation of protein kinase inhibitors.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LJ	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		


A PROCESS FOR THE PREPARATION OF CHIRAL KETONE INTERMEDIATES USEFUL FOR THE PREPARATION OF FLAVOPIRIDOL AND ANALOGS

5

Brief Description of the Invention

The present invention is directed to a process for preparing chiral compounds of the formula


I



10

The compounds of formula I are intermediates for the preparation of protein kinase inhibitors which are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. Compounds of the formula I may be used to prepare, for example, flavopiridol and analogs of the formula

II



20 and pharmaceutically acceptable salts thereof. Compounds of the formula II are disclosed in US serial number 60/017,529, filed May 10, 1996, which is incorporated by reference herein. As used in formula I, II, and throughout the specification, the symbols have the following meanings:

X is a single bond, oxygen or sulfur;

25 R¹ is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, -(CH₂)_q-NR⁷R⁸, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkyloxycarbonyl, arylalkyloxycarbonyl or aryloxycarbonyl;

R² is hydrogen, alkyl, arylalkyl, aryl, cycloalkyl, hydroxy, alkoxy, arylalkoxy, aryloxy, alkylcarbonyloxy, arylalkylcarbonyloxy, arylcarbonyloxy, carboxy, alkyloxycarbonyl, arylalkoxycarbonyl, aryloxycarbonyl, amino, -NR⁷R⁸, thiol, alkylthio, arylalkylthio or arylthio;

5 R³ is hydrogen, alkyl, arylalkyl, aryl, cycloalkyl, hydroxy, alkoxy, arylalkoxy, aryloxy, alkylcarbonyloxy, arylalkylcarbonyloxy, arylcarbonyloxy, carboxy, alkyloxycarbonyl, arylalkoxycarbonyl, cyano, nitro, -NR⁷R⁸, halogen, alkylhalo, -CHO, alkylS(O)_m- or -OC(O)NR⁷R⁸;

10 R⁴ is hydrogen, alkyl, arylalkyl, aryl, cycloalkyl, hydroxy, alkoxy, arylalkoxy, aryloxy, alkylcarbonyloxy, arylalkylcarbonyloxy, arylcarbonyloxy, carboxy, alkyloxycarbonyl, arylalkoxycarbonyl, aryloxycarbonyl, amino, -NR⁷R⁸, thiol, alkylthio, arylalkylthio or arylthio;

R⁵ is alkyl, cycloalkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl;

15 R⁶ is hydrogen, alkyl, aryl, arylalkyl, nitro, amino, -(CH₂)_n-NR⁷R⁸, halogen, hydroxy, alkoxy, carboxy, heterocycle or alkyloxycarbonyl;

R⁷ and R⁸ are independently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heterocycle or alkylcarbonyl; or R⁷ and R⁸ together with the nitrogen atom to which they are bonded can form a heterocycle;

m is an integer of 0 to 2;

20 n is an integer of 1 to 3; and

q is an integer of 2 to 5.

Description of the Invention

25 The present invention provides for a process for preparing the chiral ketone intermediates of formula I.

Listed below are definitions of various terms used to describe the compounds of the instant invention. These definitions apply to the terms as they are used throughout the specification (unless they are otherwise
30 limited in specific instances) either individually or as part of a larger group.

It should be noted that any heteroatom with unsatisfied valances is assumed to have the hydrogen atom to satisfy the valances.

The term "alkyl" or "alk" refers to optionally substituted, straight and branched chain saturated hydrocarbon groups having 1 to 12 carbon atoms.
35 Exemplary unsubstituted such groups include methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, 4,4-dimethylpentyl, octyl, 2,2,4-trimethylpentyl, nonyl, decyl, undecyl, dodecyl, and

the like. Exemplary substituents may include but are not limited to one or more of the following groups: halo (such as CCl_3 or CF_3), alkoxy, alkylthio, hydroxy, carboxy ($-\text{COOH}$), alkyloxycarbonyl, alkylcarbonyloxy, amino ($-\text{NH}_2$), $-\text{NR}^7\text{R}^8$, carbamoyl ($-\text{NHCOO}-$ or $-\text{OCONH}-$), urea ($-\text{NHCONH}-$) or thiol ($-\text{SH}$).

5 The terms "alkoxy" or "alkylthio", as used herein, denote an alkyl group as described above bonded through an oxygen linkage ($-\text{O}-$) or a sulfur linkage ($-\text{S}-$), respectively.

 The term "alkyloxycarbonyl", as used herein, denotes an alkoxy group bonded through a carbonyl group.

10 The term "alkylcarbonyl" refers to an alkyl group bonded through a carbonyl group.

 The term "alkylcarbonyloxy", as used herein, denotes an alkylcarbonyl group which is bonded through an oxygen linkage.

15 The term "cycloalkyl" refers to optionally substituted, saturated cyclic hydrocarbon ring systems, preferably containing 1 to 3 rings and 3 to 7 carbons per ring. Exemplary unsubstituted such groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. Exemplary substituents include one or more of the following groups: halogen, alkyl, alkoxy, alkyl hydroxy, amino, nitro, cyano, thiol and/or alkylthio.


20 The term "aryl" refers to monocyclic or bicyclic aromatic groups containing from 6 to 10 carbons in the ring portion, (such as phenyl or naphthyl), and may optionally be substituted with one or more groups selected from halogen, alkyl, alkoxy, alkylS(O)_m- , hydroxy, carboxy, carbamoyl, alkyloxycarbonyl, $-\text{CONR}^7\text{R}^8$, nitro, trifluoromethyl, amino and $-\text{NR}^7\text{R}^8$.

25 The term "heterocycle" or "heterocyclo" denotes optionally substituted, fully saturated or unsaturated, aromatic or non-aromatic cyclic groups having at least one heteroatom in at least one ring, preferably monocyclic or bicyclic groups having 5 or 6 atoms in each ring. The heterocyclo group
30 may, for example, have 1 or 2 oxygen atoms and/or 1 or 2 sulfur atoms, and/or 1 to 4 nitrogen atoms in the ring. Each heterocyclo group may be bonded through any carbon or heteroatom of the ring system. Exemplary heterocyclo groups include the following: thienyl, furyl, pyrrolyl, pyridyl, imidazolyl, pyrrolidinyl, piperidinyl, azepinyl, indolyl, isoindolyl, quinolinyl,
35 isoquinolinyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl, benzofurazanyl and tetrahydropyranyl. Exemplary substituents include one

or more of the following: halo, alkyl, alkoxy, hydroxy, cycloalkyl, hydroxy, nitro, cyano, amino, alkylS(O)_m- or thiol.

The term "halogen" or "halo" refers to chlorine, bromine, fluorine or iodine.

- 5 Compounds of the formula I are prepared by reacting compounds of formula III



- 10 with a chiral acid such as D tartaric acid and its derivative or hydrate, mandelic acid and derivatives thereof, malic acid and its derivatives etc. in an organic solvent such as an alcohol or other halogenated solvent to form a salt of a compound of formula I.

- 15 The salt of the compound of formula I is then treated with an aqueous base such as aqueous sodium hydroxide to remove the chiral acid and obtain the desired chiral base of formula I.

Compounds of formula III are commercially available or may be prepared by methods known to one of ordinary skill in the art.

- 20 All compounds of formula I may be prepared by the procedures described herein or by modification of the procedures described herein.

The preferred method comprises the use of the chiral acid, dibenzoyl D tartaric acid.

- 25 The advantages of the method of this invention include the high yield generation of the desired enantiomer from the racemic mixture. This process converts the opposite enantiomer in the racemic mixture to the desired enantiomer via in situ epimerization.

The preferred compounds of formula I are those where:

- 30 R¹ is alkyl;
 R² is hydrogen;
 R³ is alkoxy; and
 n is the integer 3.

The compounds of formula II, including flavopiridol (which is the title compound of Example 2), have pharmacological properties; in particular,

the compounds of formula II are inhibitors of protein kinases such as the cyclin dependent kinases (cdks), for example, cdc2 (cdk1), cdk2, and cdk4. The compounds of formula II are therefore expected to be useful in the therapy of proliferative diseases such as cancer, inflammation, and arthritis (Jorg Czech et al., "Antitumoral Activity of Flavone L 86-8275", *International Journal of Oncology* 6, 31-36 (1995); Gurmeet Kaur et al., "Growth Inhibition With Reversible Cell Cycle Arrest of Carcinoma Cells by Flavone L86-8275", *Journal of the National Cancer Institute*, 84, No. 22, 1736-1740 (1992); which are incorporated by reference herein).

More specifically, the compounds of formula II are useful in the treatment of a variety of cancers, including (but not limited to) the following:

- carcinoma, including that of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin;

- hematopoietic tumors of lymphoid lineage, including acute lymphocytic leukemia, B-cell lymphoma, and Burkett's lymphoma;

- hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias and promyelocytic leukemia;

- tumors of mesenchymal origin, including fibrosarcoma and rhabdomyosarcoma; and

- other tumors, including melanoma, seminoma, teratocarcinoma, osteosarcoma, neuroblastoma and glioma.

Due to the key role of cdks in the regulation of cellular proliferation in general, inhibitors could act as reversible cytostatic agents which may be useful in the treatment of any disease process which features abnormal cellular proliferation, e.g., neuro-fibromatosis, atherosclerosis, pulmonary fibrosis, arthritis, psoriasis, glomerulonephritis, restenosis following angioplasty or vascular surgery, hypertrophic scar formation, and endotoxic shock.

Compounds of formula II may also be useful in the treatment of Alzheimer's disease, as suggested by the recent finding that cdk5 is involved in the phosphorylation of tau protein (*J. Biochem*, 117, 741-749 (1995)).

Compounds of formula II may also act as inhibitors of other protein kinases, e.g., protein kinase C, her2, raf1, MEK1, MAP kinase, EGF receptor,

PDGF receptor, IGF receptor, PI3 kinase, wee1 kinase, Src, Ab1 and thus be effective in the treatment of diseases associated with other protein kinases.

The compounds of formula II may also be useful in combination with known anti-cancer, cytostatic, and cytotoxic agents. If formulated as a fixed
5 dose, such combination products employ the compounds of this invention within the dosage range described below and the other pharmaceutically active agent within its approved dosage range. For example, the cdc2 inhibitor olomucine has been found to act synergistically with known cytotoxic agents in inducing apoptosis (*J. Cell Sci.*, 108, 2897 (1995)).
10 Compounds of formula II may be used sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate.

The pharmacological properties of the compounds formula II may be confirmed by a number of pharmacological assays. The exemplified pharmacological assays which follow have been carried out with the
15 compounds of formula II. The compound of example 2 exhibited cdc2/cyclin B1 kinase activity with IC₅₀ values less than 10 μ M. The compound of example 2 exhibited cdk2/cyclin E kinase activity with IC₅₀ values less than 20 μ M. The compound of example 2 exhibited cdk4/cyclin D1 kinase activity with IC₅₀ values less than 100 μ M.

20

cdc2/cyclin B1 Kinase Assay

cdc2/cyclin B1 kinase activity was determined by monitoring the incorporation of ³²P into histone H1. The reaction consisted of 50 ng baculovirus expressed GST-cdc2, 75 ng baculovirus expressed GST-cyclin
25 B1, 1 μ g histone H1 (Boehringer Mannheim), 0.2 μ Ci of ³²P γ -ATP and 25 μ M ATP in kinase buffer (50 mM Tris, pH 8.0, 10 mM MgCl₂, 1 mM EGTA, 0.5 mM DTT). The reaction was incubated at 30°C for 30 minutes and then stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15% and incubated on ice for 20 minutes. The reaction was harvested onto
30 GF/C unfilter plates (Packard) using a Packard Filtermate Universal harvester, and the filters were counted on a Packard TopCount 96-well liquid scintillation counter (Marshak, D.R., Vanderberg, M.T., Bae, Y.S., Yu, I.J., *J. of Cellular Biochemistry*, 45, 391-400 (1991), incorporated by reference herein).

35

cdk2/cyclin E Kinase Assay

cdk2/cyclin E kinase activity was determined by monitoring the incorporation of ³²P into the retinoblastoma protein. The reaction consisted

of 2.5 ng baculovirus expressed GST-cdk2/cyclin E, 500 ng bacterially produced GST-retinoblastoma protein (aa 776-928), 0.2 μ Ci 32 P γ -ATP and 25 μ M ATP in kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl_2 , 5 mM EGTA, 2 mM DTT). The reaction was incubated at 30°C for 30 minutes and then stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15% and incubated on ice for 20 minutes. The reaction was harvested onto GF/C unifier plates (Packard) using a Packard Filtermate Universal harvester, and the filters were counted on a Packard TopCount 96-well liquid scintillation counter.

10

cdk4/cyclin D1 Kinase Assay

cdk4/cyclin D1 kinase activity was determined by monitoring the incorporation of 32 P into the retinoblastoma protein. The reaction consisted of 165 ng baculovirus expressed GST-cdk4, 282 ng bacterially expressed S-tag cyclin D1, 500 ng bacterially produced GST-retinoblastoma protein (aa 776-928), 0.2 μ Ci 32 P γ -ATP and 25 μ M ATP in kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl_2 , 5 mM EGTA, 2 mM DTT). The reaction was incubated at 30°C for 1 hour and then stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration of 15% and incubated on ice for 20 minutes. The reaction was harvested onto GF/C unifier plates (Packard) using a Packard Filtermate Universal harvester, and the filters were counted on a Packard TopCount 96-well liquid scintillation counter (Matsushime, H., Ewen, M.E., Strom, D.K., Kato, J-Y., Hanks, S.K., Roussel, M.F., Sherr, C.J. (1992) *Cell*, 71, 323-334, incorporated by reference herein).

15

20


25

The following examples and preparations describe the manner and process of making and using the invention and are illustrative rather than limiting. It should be understood that there may be other embodiments which fall within the spirit and scope of the invention as defined by the claims appended hereto.

30

Example 1

(R)-1-Methyl-4-(2,4,6-trimethoxyphenyl)-3-piperidinone



5

A mixture of (±)-1-methyl-4-(2,4,6-trimethoxyphenyl)-3-piperidinone (1.60 g, 5.73 mmol) and dibenzoyl-D-tartaric acid (2.28 g, 315 mmol) in 10 mL of methanol was heated at reflux temperature under argon atmosphere and it was cooled to room temperature. After stirring overnight at room temperature the precipitated solid was filtered, washed with a small amount of methanol to obtain the first crop of (R)-1-methyl-4-(2,4,6-trimethoxyphenyl)-3-piperidinone dibenzoyl-D-tartaric acid salt (2.65 g). The filtrate solution was concentrated to a volume of ca 6 mL and was stirred at ambient temperature for one day. The second crop of the chiral salt (0.24 g) was obtained by filtering the solid and washed it with a small amount of methanol.

The combined solid salt (2.89 g) was dissolved in a mixture of CH_2Cl_2 (40 mL) and aq. NaOH solution (12 mL of 0.5 NaOH), the organic solution was taken, washed with brine, dried over MgSO_4 and concentrated under reduced pressure to obtain (R)-1-methyl-4-(2,4,6-trimethoxyphenyl)-3-piperidinone (1.60 g, 76% yield) as a white solid, mp 131-133°C. $[\alpha]_D^{25} = +31^\circ\text{C}$ (MeOH, c 1.0). Chiral purity was determined by HPLC on OD Chiracel column (250x4.6 MM) eluting with 30% iso-propanol in hexane containing 0.1% triethylamine (flow rate: 1.0 mL/minute) at 254 nm.


^1H NMR (CDCl_3) δ 6.28 (s, 2 H), 4.01 (m, 1 H), 3.92 (s, 3 H), 3.88 (s, 6 H), 3.58 (m, 1 H), 3.13 (m, 1 H), 2.97 (m, 1 H), 2.61 (m, 1 H), 2.51 (s, 3 H), 2.48 (m, 1 H), 2.12 (m, 1 H) ppm;

^{13}C NMR (CDCl_3) δ 207.0, 151.5, 159.7, 109.7, 92.3, 67.7, 56.9, 56.4, 55.7, 47.2, 44.6, 30.5 ppm.

30


Example 2

(3S-cis)-2-(2-Chlorophenyl)-8-(3-hydroxy-1-methyl-4-piperidiny)-5,7-dihydroxy-4H-1-benzopyran-4-one



5

A. (3S-cis)-1-Methyl-4-(2,4,6-trimethoxyphenyl)-3- piperidinol




To a stirred solution of the title compound of Example 1 (25.0 g, 89.5 mmol) in CH_2Cl_2 (225 mL) at -76°C (dry ice-acetone bath) was added dropwise a solution of diisobutylaluminum hydride (180 mmol, 180 mL of 1 M in CH_2Cl_2) under argon atmosphere with maintaining the reaction temperature below -65°C . The reaction mixture was stirred for 3.5 hours at -76°C after the completion of addition. Trifluoroacetic acid (50 mL) was added dropwise to the reaction mixture at -76°C . After stirring the mixture for 15 minutes MeOH (250 mL) was added. It was warmed to room temperature and concentrated to obtain a solid residue, which was stirred with aqueous NaOH solution (2 N, 750 mL) for 15 minutes. The product was extracted with ethyl acetate (3x750 mL), the combined ethyl acetate solution was washed with brine, dried over Na_2SO_4 and concentrated to give a gum (25.0 g, 99%). This material was dissolved in CH_2Cl_2 and purified by flash chromatography (SiO_2 , EtOAc:MeOH: Et_3N /100:20:0.2) to afford a cis- and trans-alcohol mixture as a foam, 22.0 g. This isomeric mixture was dissolved in 30% isopropanol in hexanes and passed through a Chiracel AD column (50x50 mm, Daicel chem. Ind. Ltd) eluting with 30% isopropanol in hexanes containing 0.2% Et_3N to obtain the title compound as a pure cis-alcohol (14.1 g, 56%), mp $111-112^\circ\text{C}$ (lit. 1, $109-111^\circ\text{C}$).

^1H NMR (CDCl_3) δ 6.13 (s, 2 H), 3.82 (s, 1 H), 3.27 (s, 9 H), 3.32 (m, 1 H), 3.00 (m, 2 H), 2.30 (s, 3 H), 2.10 (m, 3 H), 1.40 (m, 1 H) ppm;
 ^{13}C NMR (CDCl_3) δ 159.6, 159.2, 111.5, 91.5, 70.4, 62.6, 57.1, 55.8, 55.3, 46.4, 36.8, 24.3 ppm; $[\alpha]_D = -53.8^\circ\text{C}$ (MeOH, c 1.0) (lit. 1, -54.13°C).


5

B. (3S-cis)-4-(3-Acetyl-2-hydroxy-4,6-dimethoxyphenyl)-1-methyl-3-piperidinol




- 10 A solution of the title A compound (13.8 g, 49 mmol) in CH_2Cl_2 (250 mL) at 0°C was added BF_3 etherate (50 mL) followed by acetic anhydride (40 mL). The resulting mixture was stirred at room temperature overnight and concentrated to remove the CH_2Cl_2 . The residue was cooled in an ice bath and quenched with MeOH (300 mL). The mixture was stirred at room
- 15 temperature for 15 minutes and concentrated *in vacuo*. The residue was dissolved in MeOH (300 mL) and stirred with 20% aqueous KOH solution (200 mL) for 48 hours. It was concentrated to remove the methanol and the residue was adjusted to pH 9.5 with 4 N hydrochloric acid. The product was extracted with CH_2Cl_2 (5x100 mL) and the combined CH_2Cl_2 extracts were
- 20 dried over Na_2SO_4 and concentrated to afford a solid. The solid obtained was purified by flash chromatography (SiO_2 ; EtOAc:MeOH: Et_3N /100:15:0.2) to obtain a solid product which was triturated with diisopropyl ether (150 mL) to give the title compound (12.5 g, 82.6%) as a light yellow solid, mp 182°C (lit. 1, $184\text{--}186^\circ\text{C}$).
- 25 ^1H NMR (CDCl_3) δ 6.11 (s, 1 H), 4.03 (s, 3 H), 4.01 (s, 3 H), 4.0 (s, 1 H), 3.50 (m, 1 H), 3.16 (m, 3 H), 2.73 (s, 3 H), 2.46 (s, 3 H), 2.36 (m, 1 H), 2.22 (m, 1 H), 1.56 (m, 1 H) ppm;
 ^{13}C NMR (CDCl_3) δ 203.3, 264.0, 163.7, 161.7, 109.9, 105.6, 86.1, 69.8, 62.2, 56.6, 55.2, 55.0, 46.0, 36.4, 32.8, 23.7 ppm; $[\alpha]_D =$
- 30 -34.5°C (MeOH, c 1.0) (lit., -32.65°C).

C. (3S-cis)-2-(2-Chlorophenyl)-8-(3-hydroxy-1-methyl-4-piperidinyI)-5,7-dimethoxy-4H-1-benzopyran-4-one



- 5 To a solution of methyl 2-chlorobenzoate (19.0 g, 111.6 mmol) and NaH (4.7 g, 95%, 186.0 mmol) in DMF (20 mL) at 0°C was added a solution of the title B compound (11.5 g, 37.2 mmol) in DMF (100 mL) with stirring. After the completion of addition the mixture was stirred at room temperature for 4 hours. The mixture was poured onto ice and the resulting solution was
- 10 adjusted to pH 10 with 1 N hydrochloric acid. The product was extracted with CH₂Cl₂ (4x150 mL). The CH₂Cl₂ extract was concentrated and the residue was diluted with CHCl₃ (100 mL). The solution was saturated with gaseous hydrogen chloride at room temperature and stirred for 1 hour. The solution was made alkaline with aqueous Na₂CO₃ solution and the organic
- 15 layer was separated. The aqueous layer was extracted with CH₂Cl₂ (3x150 mL). The combined organic solution was dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by flash chromatography (SiO₂; EtOAc:MeOH:Et₃N/100:15:0.2) to afford the title compound (9.1 g, 57%) as a foam.
- 20 ¹H NMR (CDCl₃) δ 7.74-7.52 (m, 4 H), 6.60 (s, 1 H), 6.59 (s, 1 H), 4.14 (s, 3 H), 4.11 (s, 3 H), 4.10 (s, 1 H), 3.65 (m, 1 H), 3.55 (m, 1 H), 3.18 (m, 3 H), 2.50 (s, 3 H), 2.40 (m, 1 H), 2.38 (m, 1 H), 1.73 (m, 1 H) ppm;
- ¹³C NMR (CDCl₃) δ 178.2, 163.1, 160.7, 160.4, 157.6, 133.1, 132.2, 131.3, 127.8, 114.4, 111.1, 93.1, 70.5, 63.0, 57.3, 56.9, 56.6, 46.7, 38.4, 24.7, 14.7
- 25 ppm; [α]_D = -60.5°C (MeOH, c 1.0).

D. (3S-cis)-2-(2-Chlorophenyl)-8-(3-hydroxy-1-methyl-4-piperidiny)-5,7-dihydroxy-4H-1-benzopyran-4-one




5 To a solution of the title C compound (9.0 g, 20.9 mmol) in 1,2-dichloroethane (120 mL) at 0°C was added a solution of BBr₃ (42.0 g, 168 mmol) in 1,2-dichloroethane (80 mL) with a vigorous stirring. The resulting mixture was stirred at 80°C for 8 hours and 90°C for 5 hours. It was cooled to room temperature and poured onto ice. The mixture was made alkaline
10 with aqueous Na₂CO₃ solution to pH 9-10 and the organic layer was taken. The heterogeneous aqueous layer containing desired product was washed with CH₂Cl₂ (6x150 mL). The combined organic solution was dried over Na₂SO₄ and concentrated. The residue was triturated with CH₂Cl₂ - MeOH (100:5) to obtain a yellow solid product. This solid was stirred in MeOH (100
15 mL) containing 1 N hydrochloric acid (20 mL) at room temperature until it became a clear solution. It was concentrated *in vacuo* and the residue was stirred in MeOH (20 mL) at reflux temperature for 10 minutes. It was cooled to room temperature and ethyl ether (50 mL) was added to the mixture. The precipitated solid was filtered, washed with ethyl ether three times and dried
20 to afford a solid, 6.7 g which contained the title compound methanol. This solid was dissolved in water (100 mL) and lyophilized to give the title compound (6.4 g, 67%) as a pale yellow solid, mp 195-197°C (lit. 1, 190-194°C).

¹H NMR (CD₃OD) δ 7.76 (dd, J=2.3 and 7.2 Hz, 1 H), 7.60 (m, 3 H), 6.48 (s, 1 H), 6.33 (s, 1 H), 4.27 (s, 1 H), 3.71 (m, 1 H), 3.54-3.32 (m, 3 H), 3.15 (m, 2 H), 2.87 (s, 3 H), 1.87 (m, 1 H) ppm;

¹³C NMR (CD₃OD) δ 184.0, 164.9, 164.6, 162.3, 157.7, 133.6, 132.9, 132.4, 131.9, 128.9, 111.8, 107.2, 106.0, 101.2, 68.2, 61.7, 56.7, 44.2, 37.3, 23.4; MS (ESI) m/e 402 (M+H)⁺, 400 (M-H)⁻. [α]_D = -3.3°C (MeOH, c 1.0) (lit. 1, -3.4°C).

What is Claimed is:

1. A process for the preparation of compounds of formula



5

where

R¹ is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, $-(CH_2)_q-NR^7R^8$, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkyloxycarbonyl, arylalkyloxycarbonyl or aryloxycarbonyl;

10

R² is hydrogen, alkyl, arylalkyl, aryl, cycloalkyl, hydroxy, alkoxy, arylalkoxy, aryloxy, alkylcarbonyloxy, arylalkylcarbonyloxy, arylcarbonyloxy, carboxy, alkyloxycarbonyl, arylalkoxycarbonyl, aryloxycarbonyl, amino, $-NR^7R^8$, thiol, alkylthio, arylalkylthio or arylthio;

15

R³ is hydrogen, alkyl, arylalkyl, aryl, cycloalkyl, hydroxy, alkoxy, arylalkoxy, aryloxy, alkylcarbonyloxy, arylalkylcarbonyloxy, arylcarbonyloxy, carboxy, alkyloxycarbonyl, arylalkoxycarbonyl, cyano, nitro, $-NR^7R^8$, halogen, alkylhalo, $-CHO$, $alkylS(O)_m$ - or $-OC(O)NR^7R^8$;

20

R⁷ and R⁸ are independently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heterocycle or alkylcarbonyl; or R⁷ and R⁸ together with the nitrogen atom to which they are bonded can form a heterocycle;

m is an integer of 0 to 2;


n is an integer of 1 to 3; and

q is an integer of 2 to 5;

which comprises the steps of (a) reacting a compound of formula

25

III




with a chiral acid in an organic solvent to form a salt of a compound of formula I and (b) treating the salt of a compound of formula I with an aqueous base to obtain the compounds of formula I.

- 5 2. The process as recited in Claim 1 wherein the chiral acid is D tartaric acid, its derivative or hydrate.
3. The process as recited in Claim 1 wherein the chiral acid is mandelic acid or derivatives thereof.
- 10 4. The process as recited in Claim 1 wherein the chiral acid is malic acid or its derivatives.
5. The process as recited in Claim 1 wherein the organic solvent is alcohol or a halogenated solvent.
- 15 6. The process as recited in Claim 2 wherein the organic solvent is alcohol or a halogenated solvent.
7. The process as recited in Claim 3 wherein the organic solvent is alcohol or a halogenated solvent.
- 20 8. The process as recited in Claim 4 wherein the organic solvent is alcohol or a halogenated solvent.
- 25 9. The process as recited in Claim 1 wherein the aqueous base is aqueous sodium hydroxide.
10. The process as recited in Claim 2 wherein the aqueous base is aqueous sodium hydroxide.
- 30 11. The process as recited in Claim 3 wherein the aqueous base is aqueous sodium hydroxide.
12. The process as recited in Claim 4 wherein the aqueous base is aqueous sodium hydroxide.
- 35

13. The process as recited in Claim 5 wherein the aqueous base is aqueous sodium hydroxide.
14. The process as recited in Claim 6 wherein the aqueous base is aqueous sodium hydroxide.
15. The process as recited in Claim 7 wherein the aqueous base is aqueous sodium hydroxide.
16. The process as recited in Claim 8 wherein the aqueous base is aqueous sodium hydroxide.
17. The process as recited in Claim 1 wherein
R¹ is alkyl;
R² is hydrogen;
R³ is alkoxy; and
n is the integer 3.
18. The process as recited in Claim 17 wherein the chiral acid is D tartaric acid, its derivative or hydrate, mandelic acid or derivatives thereof or malic acid or its derivatives.
19. The process as recited in Claim 18 wherein the chiral acid is dibenzoyl D tartaric acid.
20. The process as recited in Claim 18 wherein the organic solvent is alcohol or a halogenated solvent.
21. The process as recited in Claim 20 wherein the aqueous base is aqueous sodium hydroxide.

22. A process for the preparation of compounds of formula II



5 and pharmaceutically acceptable salts thereof where

X is a single bond, oxygen or sulfur;

R¹ is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, $-(CH_2)_q-NR^7R^8$, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkyloxycarbonyl, arylalkyloxycarbonyl or aryloxycarbonyl;

10 R² is hydrogen, alkyl, arylalkyl, aryl, cycloalkyl, hydroxy, alkoxy, arylalkoxy, aryloxy, alkylcarbonyloxy, arylalkylcarbonyloxy, arylcarbonyloxy, carboxy, alkyloxycarbonyl, arylalkoxycarbonyl, aryloxycarbonyl, amino, $-NR^7R^8$, thiol, alkylthio, arylalkylthio or arylthio;

15 R³ is hydrogen, alkyl, arylalkyl, aryl, cycloalkyl, hydroxy, alkoxy, arylalkoxy, aryloxy, alkylcarbonyloxy, arylalkylcarbonyloxy, arylcarbonyloxy, carboxy, alkyloxycarbonyl, arylalkoxycarbonyl, cyano, nitro, $-NR^7R^8$, halogen, alkylhalo, $-CHO$, $alkylS(O)_m-$ or $-OC(O)NR^7R^8$;

20 R⁴ is hydrogen, alkyl, arylalkyl, aryl, cycloalkyl, hydroxy, alkoxy, arylalkoxy, aryloxy, alkylcarbonyloxy, arylalkylcarbonyloxy, arylcarbonyloxy, carboxy, alkyloxycarbonyl, arylalkoxycarbonyl, aryloxycarbonyl, amino, $-NR^7R^8$, thiol, alkylthio, arylalkylthio or arylthio;

R⁵ is alkyl, cycloalkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl;

R⁶ is hydrogen, alkyl, aryl, arylalkyl, nitro, amino, $-(CH_2)_n-NR^7R^8$, halogen, hydroxy, alkoxy, carboxy, heterocycle or alkyloxycarbonyl;

25 R⁷ and R⁸ are independently hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, heterocycle or alkylcarbonyl; or R⁷ and R⁸ together with the nitrogen atom to which they are bonded can form a heterocycle;


m is an integer of 0 to 2;

n is an integer of 1 to 3; and

30

q is an integer of 2 to 5 which comprises the steps of (a) reacting a compound of formula


III



5

with a chiral acid in an organic solvent to form a salt of a compound of formula

I



- 10 (b) treating the salt of a compound of formula I with an aqueous base to obtain the compounds of formula I and (c) converting a compound of formula I to a compound of formula II.

INTERNATIONAL SEARCH REPORT

International application No. .
PCT/US97/16432**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C07D 207/26, 211/74, 223/08, 405/04

US CL : 548/525, 543; 546/196, 216; 540/596, 604

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 548/525, 543; 546/196, 216; 540/596, 604

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, MEDLINE, APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4,900,727 A (KATTIGE et al) 13 February 1990, column 7, line 25 - column 10, line 17, figures 1 and 2, example 8.	1-22
A	US 5,123,954 A (MORIYASU et al) 23 June 1992, column 2, lines 25-68.	1-21

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 18 NOVEMBER 1997	Date of mailing of the international search report 22 DEC 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer CHANA AULAKH Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No. -
PCT/US97/16432

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/16432

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule

13.1. The species are as follows:

- I. Compounds of formula I where m is equal to 0, classifiable in class 548, subclass 400+.
- II. Compounds of formula I where m is equal to 1, classifiable in class 546, subclass 184+.
- III. Compounds of formula I where m is equal to 2, classifiable in class 540, subclass 484+.

The claims are deemed to correspond to the species listed above in the following manner:

- I. Claims 1-22.
- II. Claims 1-22.
- III. Claims 1-22.

The following claims are generic: Claims 1-22.

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: There is no common core Which in the Markush Practice, is a significant structural element shared by all the alternatives; see PCT Administrative Instructions Annex B Part I (f) (i) (B) (1).

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☒ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.